A promising combination is not yet a development decision.
Early oncology combination cohorts can produce signals across efficacy, toxicity, dose and exposure that do not always point in the same direction. MedOncNORD brings the available evidence together around the regimen decision, clarifying what the data support, what they cannot distinguish and what the next cohort needs to resolve.
Early combination data can be promising without being decisive.
The development question is not whether the dataset looks interesting.
It is whether the available evidence is strong enough to support the next commitment of patients, time and capital.
- 01
Which regimen is best supported by the current evidence?
- 02
What can and cannot be concluded about the observed benefit-risk pattern? - 03
What must the next cohort resolve before the programme moves forward?
The cost of uncertainty rises when the programme moves forward.
At the same time, dose optimisation and the contribution of individual components to the overall effect of a combination regimen are receiving increasing regulatory attention in oncology development.
The evidence has to be read together.
The review brings together the evidence already available around the development decision, including efficacy, toxicity and tolerability, dose, treatment modifications, timing and exposure data where available.
What the observed activity supports, and how certain that interpretation is.
Dose and available exposure information considered in the context of the observed clinical data.
Timing, interruptions, reductions and other treatment course information relevant to interpreting the regimen.
The purpose is not to force attribution where the data cannot support it. It is to define the limits of the current evidence before the next decision is made.
Combination Decision Brief
A focused decision document built around the specific combination development question agreed at the start of the engagement.
The conclusions that remain defensible across the available evidence.
The questions the existing study design, sample size or evidence cannot resolve reliably.
The analyses, comparisons or questions for the next cohort that would most reduce uncertainty before the programme advances.
Where the data cannot distinguish between plausible explanations, the brief says so.
Useful before uncertainty becomes expensive.
Before dose or regimen selection
When several early cohort signals need to be interpreted together before selecting what advances.
Before an expansion cohort or Phase II
When an early combination story is about to drive a larger development commitment.
Before partnering or licensing
When the evidence supporting the proposed development path needs independent scrutiny.
During investment diligence
When an investor needs to understand which conclusions are supported and which remain dependent on unresolved assumptions.
A defined question. A defined scope.
Offered as scoped pilot engagements for selected early oncology combination programmes.
- You provide
Existing programme datasets or agreed diligence materials, together with the combination development question to be addressed.
- We agree
Scope, required data, deliverable, timing and fee before work starts.
- We deliver
A Combination Decision Brief focused on what the evidence supports, what remains unresolved and what should be clarified next.
- Programme data or agreed diligence materials
- NDA · data processing agreement where applicable
- Fixed scope
- Fee agreed upfront
A development question deserves a view that is not invested in the answer.
MedOncNORD provides an independent oncology-focused review of the evidence around the defined development decision. The objective is not to strengthen a preferred narrative, but to make clear where the current evidence is strong, where it is fragile and where it remains genuinely unresolved.
- Oncology biotech clinical development teams
- CMOs / medical leadership
- Business development & licensing
- Life-science investors conducting programme diligence
Clarify the evidence before the next regimen decision.
Challenge the evidence before capital or licensing follows the signal.
Independent review of the evidence supporting a combination development story before an investment, partnering or licensing decision.
Discuss a diligence question